1. Home
  2. ALGN vs MDGL Comparison

ALGN vs MDGL Comparison

Compare ALGN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALGN
  • MDGL
  • Stock Information
  • Founded
  • ALGN 1997
  • MDGL 2011
  • Country
  • ALGN United States
  • MDGL United States
  • Employees
  • ALGN N/A
  • MDGL N/A
  • Industry
  • ALGN Industrial Specialties
  • MDGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALGN Health Care
  • MDGL Health Care
  • Exchange
  • ALGN Nasdaq
  • MDGL Nasdaq
  • Market Cap
  • ALGN 9.9B
  • MDGL 9.6B
  • IPO Year
  • ALGN N/A
  • MDGL N/A
  • Fundamental
  • Price
  • ALGN $135.58
  • MDGL $445.36
  • Analyst Decision
  • ALGN Buy
  • MDGL Strong Buy
  • Analyst Count
  • ALGN 13
  • MDGL 13
  • Target Price
  • ALGN $190.50
  • MDGL $514.75
  • AVG Volume (30 Days)
  • ALGN 1.3M
  • MDGL 356.3K
  • Earning Date
  • ALGN 10-29-2025
  • MDGL 11-04-2025
  • Dividend Yield
  • ALGN N/A
  • MDGL N/A
  • EPS Growth
  • ALGN N/A
  • MDGL N/A
  • EPS
  • ALGN 5.16
  • MDGL N/A
  • Revenue
  • ALGN $3,982,622,000.00
  • MDGL $740,640,000.00
  • Revenue This Year
  • ALGN $2.08
  • MDGL $395.75
  • Revenue Next Year
  • ALGN $3.28
  • MDGL $65.73
  • P/E Ratio
  • ALGN $26.28
  • MDGL N/A
  • Revenue Growth
  • ALGN 0.56
  • MDGL 864.21
  • 52 Week Low
  • ALGN $122.00
  • MDGL $265.00
  • 52 Week High
  • ALGN $246.19
  • MDGL $469.95
  • Technical
  • Relative Strength Index (RSI)
  • ALGN 52.67
  • MDGL 57.62
  • Support Level
  • ALGN $133.71
  • MDGL $399.00
  • Resistance Level
  • ALGN $150.78
  • MDGL $434.98
  • Average True Range (ATR)
  • ALGN 4.46
  • MDGL 20.98
  • MACD
  • ALGN 0.65
  • MDGL -0.96
  • Stochastic Oscillator
  • ALGN 31.31
  • MDGL 67.79

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Share on Social Networks: